ArticleAnalytical chemistry2025
High-Throughput Monoclonal Antibody Peptide Mapping Using 15-s HPLC Gradients Coupled with Cyclic Ion Mobility-Mass Spectrometry.
Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Identification and quantification of critical quality attributes (CQAs) such as sequence variants and post-translational modifications (PTMs) at the residue level are essential for ensuring the safety and efficacy of monoclonal antibody (mAb) therapeutics. Peptide mapping using liquid chromatography coupled to mass spectrometry (LC-MS) allows for the simultaneous monitoring of multiple CQAs, but conventional methods often suffer from low throughput, limiting their utility in applications requiring fast analysis. Here, we present a multidimensional high-throughput peptide mapping workflow that combines fast LC with cyclic ion mobility-mass spectrometry (LC-cIM-MS) for the high-resolution analysis of mAb tryptic digests. A 15-s LC gradient coupled to single-pass cIM-MS achieved a peak capacity of 490 and allowed for a 96-well plate to be analyzed in 37 min, including time for column re-equilibration and autosampler needle washing between each injection. The method yielded a 97% sequence coverage. Repeatability assessments demonstrated robust retention time, arrival time, and peak intensity reproducibility, and a linear dynamic range was observed across nearly 2 orders of magnitude. Mobility-aligned collision-induced dissociation was used to unambiguously localize PTM sites. The fast LC-cIM-MS platform provided site-specific tracking of the oxidation, deamidation, and isomerization kinetics during forced degradation studies. The method offers an approach to assessing CQAs in high-throughput analysis applications such as stability studies, formulation screening, and process monitoring and has the potential to accelerate mAb development and manufacturing. These results also demonstrate the potential of fast multidimensional separations for complex sample analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.